CR9347A - Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos - Google Patents

Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos

Info

Publication number
CR9347A
CR9347A CR9347A CR9347A CR9347A CR 9347 A CR9347 A CR 9347A CR 9347 A CR9347 A CR 9347A CR 9347 A CR9347 A CR 9347A CR 9347 A CR9347 A CR 9347A
Authority
CR
Costa Rica
Prior art keywords
treatment
hyperproliferative disorders
pirimidine derivatives
pirimidine
derivatives
Prior art date
Application number
CR9347A
Other languages
English (en)
Inventor
A Dixon Julie
Nagarthnam Dhanapalan
Zhang Lei
Yi Lin
Chen Yuanwei
Chen Jianqing
R Bear Brian
Brands Michael
Hillisch Alexander
Bierer Donald
Wang Ming
Fu Wenlang
F Hentemann Martin
Bullion Ann-Marle
Patel Manoj
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36624969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of CR9347A publication Critical patent/CR9347A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Este unvento se relaciona con ciertos compuestos y composiciones del ácido bifenil-4-yl-carbonilamino y métodos para el tratamiento y prevención de la obesidad y enfermedades relacionadas.
CR9347A 2005-03-10 2007-08-28 Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos CR9347A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66056105P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
CR9347A true CR9347A (es) 2007-12-17

Family

ID=36624969

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9347A CR9347A (es) 2005-03-10 2007-08-28 Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos

Country Status (23)

Country Link
US (1) US20110098301A1 (es)
EP (1) EP1858882A1 (es)
JP (1) JP2008533042A (es)
KR (1) KR20080004488A (es)
CN (1) CN101151258A (es)
AR (1) AR053554A1 (es)
AU (1) AU2006223199A1 (es)
BR (1) BRPI0609022A2 (es)
CA (1) CA2601257A1 (es)
CR (1) CR9347A (es)
DO (1) DOP2006000061A (es)
EA (1) EA200701930A1 (es)
GT (1) GT200600105A (es)
IL (1) IL185498A0 (es)
MA (1) MA29377B1 (es)
MX (1) MX2007010102A (es)
NO (1) NO20074964L (es)
PE (1) PE20061067A1 (es)
TN (1) TNSN07322A1 (es)
TW (1) TW200724537A (es)
UY (1) UY29414A1 (es)
WO (1) WO2006099231A1 (es)
ZA (1) ZA200708591B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001477A4 (en) * 2006-03-20 2010-07-21 Bayer Healthcare Llc COMBINATION OF PACLITAXEL
CN101765591B (zh) * 2007-07-26 2013-11-27 诺华股份有限公司 用于治疗炎性或过敏性病症的嘧啶衍生物
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
CN103228274A (zh) 2010-10-01 2013-07-31 拜耳知识产权有限责任公司 包含取代的n-(2-芳基氨基)芳基磺酰胺的组合
CN103270026A (zh) 2010-12-21 2013-08-28 诺瓦提斯公司 作为vps34抑制剂的联-杂芳基化合物
CN103492370B (zh) 2011-04-22 2016-10-26 西格诺药品有限公司 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
WO2015030847A1 (en) 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US9638690B2 (en) 2014-11-07 2017-05-02 The University Of British Columbia Compounds and compositions for use as alkylating agent sensors and methods of use thereof
CA2975260A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA2993173C (en) 2015-07-24 2023-10-03 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
TWI609028B (zh) 2016-05-06 2017-12-21 財團法人工業技術研究院 共聚物與含其之樹脂組合物、封裝膜及封裝結構
CN111518078B (zh) * 2020-05-30 2021-02-26 南方医科大学 一种含氨基吡啶的嘧啶类化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3089480B2 (ja) * 1990-09-20 2000-09-18 ソニー株式会社 フリットシール装置
MXPA04007196A (es) * 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
EP1470121B1 (en) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
JP4948173B2 (ja) * 2003-10-10 2012-06-06 ニツポネツクス・インコーポレーテツド 過剰増殖性疾患治療用ピリミジン誘導体

Also Published As

Publication number Publication date
UY29414A1 (es) 2006-10-02
AU2006223199A1 (en) 2006-09-21
ZA200708591B (en) 2009-01-28
BRPI0609022A2 (pt) 2010-01-12
CA2601257A1 (en) 2006-09-21
AR053554A1 (es) 2007-05-09
IL185498A0 (en) 2008-01-06
TNSN07322A1 (en) 2008-12-31
EA200701930A1 (ru) 2008-02-28
KR20080004488A (ko) 2008-01-09
MA29377B1 (fr) 2008-04-01
MX2007010102A (es) 2007-10-12
DOP2006000061A (es) 2006-09-30
US20110098301A1 (en) 2011-04-28
EP1858882A1 (en) 2007-11-28
WO2006099231A1 (en) 2006-09-21
TW200724537A (en) 2007-07-01
CN101151258A (zh) 2008-03-26
GT200600105A (es) 2007-02-14
NO20074964L (no) 2007-12-06
PE20061067A1 (es) 2006-11-30
JP2008533042A (ja) 2008-08-21

Similar Documents

Publication Publication Date Title
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
ECSP10010035A (es) Amidas heterocíclicas y sus métodos de uso
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX2012006730A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas.
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
NO20084328L (no) Nye forbindelser
CR11818A (es) Derivados de triazol utiles para el tratamiento de enfermedades
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)